NEW YORK – NeoGenomics announced Tuesday a 51 percent year-over-year uptick in its third quarter revenues, with growth in both its clinical services and pharma services businesses.
For the three months ended Sept. 30, total revenues reached $104.7 million, up from $69.1 million in Q3 2018. It beat the analysts' average estimate of $99.1 million.
Organic revenue growth was greater than 20 percent, the company said.